Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial Life Science Investing
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026 Life Science Investing
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus Life Science Investing
NRx Pharmaceuticals Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System Life Science Investing
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants Life Science Investing
Exo-Top, NurExone's wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico Life Science Investing
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer Life Science Investing
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors Life Science Investing
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Life Science Investing
FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance Pharmaceutical Investing
